<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Debrecen-Hungary_favorite"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Debrecen-Hungary/favorite">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Debrecen-Hungary/favorite&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Debrecen-Hungary/favorite&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Debrecen-Hungary/favorite&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Debrecen-Hungary/favorite" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform">Â </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Debrecen-Hungary/favorite</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2010.igem.org</H3><TABLE><TBODY><TR valign="top" style="margin-right: 0px;"><TD width="1100px" style="padding: 0 0px 0px 0px; background-color:#ede8e2"><DIV class="MenuBar" id="navi"><UL><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team" style="color: white"> Team</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/meetteam"><SPAN><SPAN>Meet the Team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/gallery"><SPAN><SPAN>Gallery</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team#about"><SPAN><SPAN>About The team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team#Lab"><SPAN><SPAN>About The Lab</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team#deoec"><SPAN><SPAN>About The University</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team#debrecen"><SPAN><SPAN>About  Debrecen</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team#cube"><SPAN><SPAN>About  Rubiks's Cube</SPAN></SPAN></A></LI></UL><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project" style="color: white"> Project</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project#abs"><SPAN><SPAN>Abstract</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project#intro"><SPAN><SPAN>Introduction</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project#Results"><SPAN><SPAN>Results</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project#Plans"><SPAN><SPAN>Plans, Possibilities</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/project#BBF_RFC_64_:_Building_Protein_Domain_Based_Composite_Biobricks_for_Mammalian_Expression_Systems"><SPAN><SPAN>RFC 64 suggestion</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/indicontibi"><SPAN><SPAN>Members Contribution</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts" style="color: white"> Parts</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts#LBD"><SPAN><SPAN>LBD</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts#DBD"><SPAN><SPAN>DBD</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts#other"><SPAN><SPAN>Other basic parts</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts#composite"><SPAN><SPAN>Composite Parts</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/favorite"><SPAN><SPAN>Favorite Parts</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/protocols" style="color: white"> Protocols</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/protocols#Contents"><SPAN><SPAN>Cloning Team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/protocols#Mini_Prep"><SPAN><SPAN>Molecular work team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/protocols#Gel_electrophoresis"><SPAN><SPAN>Tissue culture team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/protocols#Measuring_Luciferase_activity_with_the_Victor_plate_reader"><SPAN><SPAN>Luciferase Team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/sponsors" style="color: white"> Sponsors</A></LI><LI><A style="color: white"> Tools</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/sitemap"><SPAN><SPAN>Site Map</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/minimals"><SPAN><SPAN>The Minimals</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/safety"><SPAN><SPAN>Safety</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/Team_meetings"><SPAN><SPAN>Team Meetings</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/links"><SPAN><SPAN>Links</SPAN></SPAN></A></LI><LI><A style="color: white"> Side Projects</A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/arsenic"><SPAN><SPAN>Arsenic Project</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/AKG_team"><SPAN><SPAN>AKG team</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/video_project"><SPAN><SPAN>Video Project</SPAN></SPAN></A></LI><LI><A href="https://2010.igem.org/Team:Debrecen-Hungary/on_the_media"><SPAN><SPAN>On The Media</SPAN></SPAN></A></LI></DIV></TD></TR></TBODY></TABLE><TABLE id="toc" class="toc"><TBODY><TR><TD><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#Favorite_parts_of_Team:_Debrecen-Hungary"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext">Favorite parts of Team: Debrecen-Hungary</SPAN></A></LI><LI class="toclevel-2 tocsection-2"><A href="#TRE-Gal4-PXR-PolyA_in_PSB1A3_.28expression_vector.29"><SPAN class="tocnumber">1.1</SPAN><SPAN class="toctext">TRE-Gal4-PXR-PolyA in PSB1A3 (expression vector)</SPAN></A></LI><LI class="toclevel-3 tocsection-3"><A href="#Design_Notes"><SPAN class="tocnumber">1.1.1</SPAN><SPAN class="toctext">Design Notes</SPAN></A></LI><LI class="toclevel-3 tocsection-4"><A href="#Source"><SPAN class="tocnumber">1.1.2</SPAN><SPAN class="toctext">Source</SPAN></A></LI><LI class="toclevel-3 tocsection-5"><A href="#Ligand"><SPAN class="tocnumber">1.1.3</SPAN><SPAN class="toctext">Ligand</SPAN></A></LI><LI class="toclevel-3 tocsection-6"><A href="#Applications"><SPAN class="tocnumber">1.1.4</SPAN><SPAN class="toctext">Applications</SPAN></A></LI><LI class="toclevel-3 tocsection-7"><A href="#References"><SPAN class="tocnumber">1.1.5</SPAN><SPAN class="toctext">References</SPAN></A></LI></UL><LI class="toclevel-2 tocsection-8"><A href="#Gal4-EcR_Chimeric_nuclear_receptor"><SPAN class="tocnumber">1.2</SPAN><SPAN class="toctext">Gal4-EcR Chimeric nuclear receptor</SPAN></A></LI><LI class="toclevel-3 tocsection-9"><A href="#Design_Notes_2"><SPAN class="tocnumber">1.2.1</SPAN><SPAN class="toctext">Design Notes</SPAN></A></LI><LI class="toclevel-3 tocsection-10"><A href="#Source_2"><SPAN class="tocnumber">1.2.2</SPAN><SPAN class="toctext">Source</SPAN></A></LI><LI class="toclevel-3 tocsection-11"><A href="#Ligand_2"><SPAN class="tocnumber">1.2.3</SPAN><SPAN class="toctext">Ligand</SPAN></A></LI><LI class="toclevel-3 tocsection-12"><A href="#Physiological_functions_of_EcR"><SPAN class="tocnumber">1.2.4</SPAN><SPAN class="toctext">Physiological functions of EcR</SPAN></A></LI><LI class="toclevel-3 tocsection-13"><A href="#Potential_applications_of_GAL4-EcR_LBD"><SPAN class="tocnumber">1.2.5</SPAN><SPAN class="toctext">Potential applications of GAL4-EcR LBD</SPAN></A></LI><LI class="toclevel-3 tocsection-14"><A href="#Applications_2"><SPAN class="tocnumber">1.2.6</SPAN><SPAN class="toctext">Applications</SPAN></A></LI><LI class="toclevel-3 tocsection-15"><A href="#References_2"><SPAN class="tocnumber">1.2.7</SPAN><SPAN class="toctext">References</SPAN></A></LI><LI class="toclevel-2 tocsection-16"><A href="#Gal4-ER_Chimeric_nuclear_receptor"><SPAN class="tocnumber">1.3</SPAN><SPAN class="toctext">Gal4-ER Chimeric nuclear receptor</SPAN></A></LI><LI class="toclevel-3 tocsection-17"><A href="#Design_Notes_3"><SPAN class="tocnumber">1.3.1</SPAN><SPAN class="toctext">Design Notes</SPAN></A></LI><LI class="toclevel-3 tocsection-18"><A href="#Source_3"><SPAN class="tocnumber">1.3.2</SPAN><SPAN class="toctext">Source</SPAN></A></LI><LI class="toclevel-3 tocsection-19"><A href="#Ligand_3"><SPAN class="tocnumber">1.3.3</SPAN><SPAN class="toctext">Ligand</SPAN></A></LI><LI class="toclevel-3 tocsection-20"><A href="#Physiological_function_of_ER"><SPAN class="tocnumber">1.3.4</SPAN><SPAN class="toctext">Physiological function of ER</SPAN></A></LI><LI class="toclevel-3 tocsection-21"><A href="#Possible_applications_of_GAL4-ER"><SPAN class="tocnumber">1.3.5</SPAN><SPAN class="toctext">Possible applications of GAL4-ER</SPAN></A></LI><LI class="toclevel-3 tocsection-22"><A href="#Applications_3"><SPAN class="tocnumber">1.3.6</SPAN><SPAN class="toctext">Applications</SPAN></A></LI><LI class="toclevel-3 tocsection-23"><A href="#References_3"><SPAN class="tocnumber">1.3.7</SPAN><SPAN class="toctext">References</SPAN></A></LI></TD></TR></TBODY></TABLE><H1><SPAN class="mw-headline" id="Favorite_parts_of_Team:_Debrecen-Hungary"><B>Favorite parts of Team: Debrecen-Hungary</B></SPAN></H1><P><A href="https://2010.igem.org/Team:Debrecen-Hungary/parts#Chimeric_Nuclear_Receptors_-_Composite_Parts" class="external text" rel="nofollow"><B>13 composite parts</B></A> have been created, including two expression vectors produced from standard BioBrick parts. In this section we collected the three favorite parts which showed high expression level and functional activity in the transfected cells.
</P><H2><SPAN class="mw-headline" id="TRE-Gal4-PXR-PolyA_in_PSB1A3_.28expression_vector.29"><A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364332" class="external text" rel="nofollow">TRE-Gal4-PXR-PolyA in PSB1A3 (expression vector)</A></SPAN></H2><P>Expression vector from standard BioBrick parts, expressing Gal4 - human Pregnane X receptor LBD composite part.
</P><P>The Gal4-PXR Chimeric nuclear receptor is an artificial eukaryotic TF made of Gal4 DBD (DNA Binding Domain) and H. sapiens nuclear hormone receptor LBD (Ligand Binding Domain) which can be expressed by this expression vector.
</P><P>The minimal CMV promoter ensures a continuous expression of the chimeric construct, but furthermore it can be expressed in an inducible form using the Tetracyclin-controlled transcriptional activation system. 
<A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364332" class="external text" rel="nofollow">Go to the official parts registry page for this part</A></P><P>PXR LBD
</P><P>PXR is a xenobiotic-activated member of the nuclear receptor superfamily of transcription factors. PXR is involved in transcriptional induction of hepatic xenobiotic-catabolizing cytochrome 3A enzymes, playing a fundamental role in protecting body tissues from toxic bile acids. PXR is almost exlcusively expressed in the gastrointestinal system (stomach, duodenum, jejunum, ileum, colon and gall bladder) and liver, with lower levels in the kidney and ovary. PXR dysfunction is associated with immune disorders (sclerosing cholangitis, inflammatory bowel disease) and biliary primary cirrhosis.
</P><P>Gal4 DBD
</P><P>This protein is a positive regulator for the gene expression of the galactose-induced genes such as GAL1, GAL2, GAL7, GAL10, and MEL1 which encode for the enzymes used to convert galactose to glucose. This protein contains a fungal Zn(2)-Cys(6) binuclear cluster domain.
</P><P>TRE-CMV
</P><P>The Tetracycline Response Element (TRE) is recognized and bound by the Tetracycline repressor (TetR) protein. The TRE consists of 7 repeats separated by spacer sequences and placed upstream of CMV minimal promoter that has basal expession in the abscence of bound TetR. Tetracycline derivatives (e.g. doxycycline) bind TetR and render it incapable of binding to TRE, thereby forcing the expression of target genes.
</P><P>PolyA
</P><P>The PolyA tail of mRNA has multiple adenilates which is important for the nuclear export, translation and stability of mRNA in eukaryotes. 
</P><P>This composite artificial transcription factor will activate any reporter or any gene in general that has a UAS (Upper Activating Sequence) 3' of it's promoter. The usual binding sites of reporters, contain multiple UAS elements. In order to have a POPS output, the LBD has to recruit activators in the cell. This can be initiated by ligand binding or by recruiting a protein that has a fused strong activator like the VP activator. 
</P><P>With this system NHR (Nuclear Hormone Receptor) ligands or NHR interacting partners can be screened. 
</P><P>The NHR: cofactor-VP interaction should be also broken by a potential ligand binding, this is why this setup is also suitable for ligand identification. The benefit of the cofactor-VP interaction test is that the dynamic range of the assay is much higher than the dynamic range of the normal Gal4-NHR ligand activation assay.
</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:326px;"><DIV class="thumbcaption">Structure of human Pregnan X receptor ligand binding domain in complex with the macrolide antibiotic Rifampicin.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:361px;"><DIV class="thumbcaption">3D structure of dimerized Gal4 DNA binding domain.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:427px;"><DIV class="thumbcaption">pSB1A3-TRE-Gal4-PXR</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:367px;"><DIV class="thumbcaption">Picture of gel electrophoresis: TRE-Gal4-PXR-PolyA in pSB1A3 results a new expression vector from standard Biobrick parts. The TRE-Gal4-PXR LBD-PolyA insert is 1682 bp long, without polyA which was inserted in the last step is 191 bp shorter.</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="Design_Notes">Design Notes</SPAN></H3><P>Compatible with RFC-10 and RFC-25.
</P><H3><SPAN class="mw-headline" id="Source">Source</SPAN></H3><P>Artificial and human PXR LBD.
</P><H3><SPAN class="mw-headline" id="Ligand">Ligand</SPAN></H3><P>PXR is activated by a large number of endogenous and exogenous chemicals including steroids, antibiotics, antimycotics, bile acids, hyperforin, a constituent of the herbal antidepressant St. John's Wort, and many other herbal compounds.
</P><P>PXR is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin.
</P><H3><SPAN class="mw-headline" id="Applications">Applications</SPAN></H3><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:485px;"><DIV class="thumbcaption">Picture of Western blot: Gal4-PXR composite construct is highly expressed in the expression vector created from pSB1A3</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:523px;"><DIV class="thumbcaption">Picture of Western blot: Gal4-PXR composite construct is highly expressed in the expression vector created from pSB1A3</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:452px;"><DIV class="thumbcaption">Test of pCDNA/pSB1A3-GAL4-PXR/EcR-LBD activity</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:452px;"><DIV class="thumbcaption">Test of PXR:RXR interaction</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="References">References</SPAN></H3><P>Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. Gene. 2001 Mar 7;265(1-2):11-23.
</P><P>D R Gallie. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991 5: 2108-2116
</P><P>1.Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). &quot;The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions&quot;. J. Clin. Invest. 102 (5): 1016â23. doi:10.1172/JCI3703.
</P><P>Ana Traven, Branka Jelicic &amp; Mary Sopta. &quot;Yeast Gal4: a transcriptional paradigm revisited&quot;. EMBO reports (2006) 7, 496 - 499.
</P><H2><SPAN class="mw-headline" id="Gal4-EcR_Chimeric_nuclear_receptor"><A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364326" class="external text" rel="nofollow">Gal4-EcR Chimeric nuclear receptor</A></SPAN></H2><P>Gal4 DBD - Ecdysone receptor LBD
</P><P>Artificial eukaryotic TF made of Gal4 DBD (DNA Binding Domain) and D. Melanogaster nuclear hormone receptor LBD (Ligand Binding Domain).
<A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364326" class="external text" rel="nofollow">Go to the official parts registry page for this part</A></P><P>EcR LBD
</P><P>The ecdysone receptor is a nuclear receptor found in arthropods, where it controls development and contributes to other processes such as reproduction. The receptor is a non-covalent heterodimer of two proteins, the EcR protein and ultraspiracle protein (USP). It binds to and is activated by ecdysteroids. Pulses of 20-hydroxyecdysone occur during insect development, whereupon this hormone binds to the ecdysone receptor, a ligand-activated transcription factor found in the nuclei of insect cells. This in turn leads to the activation of many other genes, which ultimately causes physiological changes that result in ecdysis (moulting).
</P><P>Gal4 DBD
</P><P>This protein is a positive regulator for the gene expression of the galactose-induced genes such as GAL1, GAL2, GAL7, GAL10, and MEL1 which encode for the enzymes used to convert galactose to glucose. This protein contains a fungal Zn(2)-Cys(6) binuclear cluster domain.
</P><P>This composite artificial transcription factor will activate any reporter or any gene in general that has a UAS (Upper Activating Sequence) 3' of it's promoter. The usual binding sites of reporters, contain multiple UAS elements. In order to have a POPS output, the LBD has to recruit activators in the cell. This can be initiated by ligand binding or by recruiting a protein that has a fused strong activator like the VP activator.
</P><P>With this system NHR (Nuclear Hormone Receptor) ligands or NHR interacting partners can be screened.
</P><P>The NHR: cofactor-VP interaction should be also broken by a potential ligand binding, this is why this setup is also suitable for ligand identification. The benefit of the cofactor-VP interaction test is that the dynamic range of the assay is much higher than the dynamic range of the normal Gal4-NHR ligand activation assay.
</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:431px;"><DIV class="thumbcaption">Picture of Ecdysone receptor USP (Ultraspiracle) heterodimer. Ponasterone A a specific agonist bound to the Ecdysone receptor ligand binding domain.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:361px;"><DIV class="thumbcaption">3D structure of dimerized Gal4 DNA binding domain.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:354px;"><DIV class="thumbcaption">Picture of gel electrophoresis: Gal4-EcR in pSB1C3 resulting an insert of 1142 bp.</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="Design_Notes_2">Design Notes</SPAN></H3><P>Artificial and arthropode EcR
</P><H3><SPAN class="mw-headline" id="Source_2">Source</SPAN></H3><P>Compatible with RFC-10 and RFC-25.
</P><H3><SPAN class="mw-headline" id="Ligand_2">Ligand</SPAN></H3><P>Ecdysteroids
</P><P>Ecdysteroids  are  insect  moulting  and  sex  hormones  which  include  ecdysone  and 
its  homologues  such  as  20-hydroxyecdysone.  Ecdysteroids  also  occur  in  other 
invertebrates where they can play a different role. They also appear in many plants 
mostly  as  a  protection  agents  (toxins  or  antifeedants)  against  herbivore  insects. 
These  phytoecdysteroids  have  medicinal  value  and  are  part  of  herbal  adaptogenic 
remedies like cordyceps.
</P><H3><SPAN class="mw-headline" id="Physiological_functions_of_EcR">Physiological functions of EcR</SPAN></H3><P>Pulses of 20-hydroxyecdysone occur during insect development, whereupon this hormone binds to the ecdysone receptor, a ligand-activated transcription factor found in the nuclei of insect cells. This in turn leads to the activation of many other genes, as evidenced by chromosomal puffing at over a hundred sites. Ultimately the activation cascade causes physiological changes that result in ecdysis (moulting). 
</P><H3><SPAN class="mw-headline" id="Potential_applications_of_GAL4-EcR_LBD">Potential applications of GAL4-EcR LBD</SPAN></H3><P>By the addition of lipid ligands(ecdysteroids), the created system activates the expression of any kind of genes fused to UAS (upstream activation seqence)previously. Also can be used as a lipid sensor by activating reporter genes (e.g. Luciferase).
</P><H3><SPAN class="mw-headline" id="Applications_2">Applications</SPAN></H3><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:561px;"><DIV class="thumbcaption">Picture of gel electrophoresis: Gal4-EcR in pCDNA3.1 resulting an insert of 1142 bp.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:510px;"><DIV class="thumbcaption">Picture of Western blot: Gal4-EcR composite construct is expressed after transferring it into pCDNA3.1</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:521px;"><DIV class="thumbcaption">Picture of Western blot: Gal4-EcR composite construct is highly expressed after transferring it into pCDNA3.1</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:452px;"><DIV class="thumbcaption">Test of pCDNA/pSB1A3-GAL4-PXR/EcR-LBD activity</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="References_2">References</SPAN></H3><P>Riddiford LM, Cherbas P, Truman JW (2000). &quot;Ecdysone receptors and their biological actions&quot;. Vitam. Horm. 60: 1â73.
</P><P>Henrich VC (2005). &quot;The ecdysteroid receptor&quot;. in Sarjeet S. Gill; Gilbert, Lawrence I.; Kostas Iatrou. Comprehensive molecular insect science. Amsterdam: Elsevier. pp. 243â285.
</P><P>Koelle MR, Talbot WS, Segraves WA, Bender MT, Cherbas P, Hogness DS (October 1991). &quot;The Drosophila EcR gene encodes an ecdysone receptor, a new member of the steroid receptor superfamily&quot;. Cell 67 (1): 59â77.
</P><H2><SPAN class="mw-headline" id="Gal4-ER_Chimeric_nuclear_receptor"><A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364327" class="external text" rel="nofollow">Gal4-ER Chimeric nuclear receptor</A></SPAN></H2><P>Gal4 DBD - human Estrogen Receptor LBD
</P><P>Artificial eukaryotic TF made of Gal4 DBD (DNA Binding Domain) and H. Sapiens nuclear hormone receptor LBD (Ligand Binding Domain)
<A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K364327" class="external text" rel="nofollow">Go to the official parts registry page for this part</A></P><P>ER LBD
</P><P>ER-Î± is a 17Î²-estradiol-activated steroid receptor member of the nuclear receptor superfamily of transcription factors. It has a variety of central physiological roles, including those involved in maintenance of the reproductive, cardiovascular, musculoskeletal and central nervous systems. ER-Î± is expressed at low to moderate levels in major physiological systems (central nervous system (CNS), endocrine, metabolic, gastrointestinal, immune, reproductive, cardiovascular, respiratory and structural), with peaks of expression in the pituitary, ovary, uterus and vas deferens. ER-Î± dysfunction is associated with cancer, cardiovascular system defects, hematological system defects, immune and inflammation diseases, metabolic defects, reproductive defects.
</P><P>Gal4 DBD
</P><P>This protein is a positive regulator for the gene expression of the galactose-induced genes such as GAL1, GAL2, GAL7, GAL10, and MEL1 which encode for the enzymes used to convert galactose to glucose. This protein contains a fungal Zn(2)-Cys(6) binuclear cluster domain.
</P><P>This composite artificial transcription factor will activate any reporter or any gene in general that has a UAS (Upper Activating Sequence) 3' of it's promoter. The usual binding sites of reporters, contain multiple UAS elements. In order to have a POPS output, the LBD has to recruit activators in the cell. This can be initiated by ligand binding or by recruiting a protein that has a fused strong activator like the VP activator. 
</P><P>With this system NHR (Nuclear Hormone Receptor) ligands or NHR interacting partners can be screened. 
</P><P>The NHR: cofactor-VP interaction should be also broken by a potential ligand binding, this is why this setup is also suitable for ligand identification. The benefit of the cofactor-VP interaction test is that the dynamic range of the assay is much higher than the dynamic range of the normal Gal4-NHR ligand activation assay.
</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:296px;"><DIV class="thumbcaption">Crystal structure of the estrogen receptor alpha ligand binding domain complexed with an ether estradiol compound</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:361px;"><DIV class="thumbcaption">3D structure of dimerized Gal4 DNA binding domain.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:535px;"><DIV class="thumbcaption">Picture of gel electrophoresis: Gal4-ER in pSB1C3 resulting an insert of 1202 bp.</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="Design_Notes_3">Design Notes</SPAN></H3><P>Compatible with RFC-10 and RFC-25.
</P><H3><SPAN class="mw-headline" id="Source_3">Source</SPAN></H3><P>Artificial and Human ER (of the nuclear hormone receptor superfamily).
</P><H3><SPAN class="mw-headline" id="Ligand_3">Ligand</SPAN></H3><P>Estrogens
</P><P>Estrogens (AmE), oestrogens (BE), or Åstrogens, are a group of steroid compounds, 
named  for  their  importance  in  the  estrous  cycle,  and  functioning  as  the  primary 
female  sex  hormone.  Their  name  comes  from  estrus/oistros  (period  of  fertility  for 
female mammals) + gen/gonos = to generate.
</P><P>Estrogens are synthesized in all vertebrates as well as some insects. The presence 
of  these  steroids  in  both  vertebrate  and  insects  suggests  that  estrogenic  sex 
hormones have an ancient history.
</P><P>Estrogens  are  used  as  part  of  some  oral  contraceptives,  in  estrogen  replacement 
therapy  for  postmenopausal  women,  and  in  hormone  replacement  therapy  for  trans 
women.
</P><P>Like inside  the  cell,  they  bind  to  and  activate  estrogen  receptors  which  in  turn  modulate the
G protein-coupled receptor, GPR30.
</P><H3><SPAN class="mw-headline" id="Physiological_function_of_ER">Physiological function of ER</SPAN></H3><P>In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.
</P><H3><SPAN class="mw-headline" id="Possible_applications_of_GAL4-ER">Possible applications of GAL4-ER</SPAN></H3><P>By the addition of lipid ligand, the created system activates the expression of any kind of genes fused to UAS(upstream activation seqence)previously. Also can be used as a lipid sensor by activating reporter genes (e.g. Luciferase).
</P><H3><SPAN class="mw-headline" id="Applications_3">Applications</SPAN></H3><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:522px;"><DIV class="thumbcaption">Picture of gel electrophoresis: Gal4-ER in pCDNA3.1 resulting an insert of 1202 bp.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:502px;"><DIV class="thumbcaption">Test of pCDNA-GAL4-ER-LBD activity</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="References_3">References</SPAN></H3><P>Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006). &quot;International Union of Pharmacology. LXIV. Estrogen receptors&quot;. Pharmacol. Rev. 58 (4): 773â81. doi:10.1124/pr.58.4.8.
</P><P>Levin ER (2005). &quot;Integration of the extranuclear and nuclear actions of estrogen&quot;. Mol. Endocrinol. 19 (8): 1951â9. doi:10.1210/me.2004-0390.
</P><P>Leung YK, Mak P, Hassan S, Ho SM (August 2006). &quot;Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling&quot;. Proc Natl Acad Sci USA 103 (35): 13162â7.
</P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2010.igem.org/Team:Debrecen-Hungary/favorite">http://2010.igem.org/Team:Debrecen-Hungary/favorite</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Debrecen-Hungary/favorite" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Debrecen-Hungary/favorite" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Debrecen-Hungary/favorite&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Debrecen-Hungary/favorite&amp;oldid=181502" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2010.igem.org:Privacy_policy" title="2010.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2010.igem.org:General_disclaimer" title="2010.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>